Compounded medication denied? We cite USP 795/797/800, DQSA §503A vs §503B, and the FDA bulks list directly.

Why compounded-medication denials are different

Compounded prescriptions sit in a regulatory zone most insurer reviewers and many prescribers find unfamiliar. Compounded drugs are not "FDA-approved" in the conventional sense; they are produced under the federal compounding statute codified by the Drug Quality and Security Act of 2013 (DQSA), which split traditional patient-specific compounding (§503A) from outsourcing-facility compounding (§503B). Insurers routinely conflate "not FDA-approved" with "experimental" and deny on that basis — even when the active substance is on the FDA 503A bulks list, the compounding pharmacy meets every USP standard, and a verified excipient allergy makes the commercial product literally dangerous to the patient.

The good news is that the federal framework, the USP General Chapters, and the FDA lists are unambiguous. A successful appeal cites DQSA §503A or §503B, USP 795 / 797 / 800, the FDA 503A bulks list, the FDA "demonstrably difficult to compound" list, and the controlling clinical guideline (NAMS, Endocrine Society, Younger LDN, Wilkinson ketamine). When all five anchors are in the letter, the denial usually reverses.

This guide covers compounded medications other than GLP-1 agonists — bioidentical hormone replacement (BHRT), low-dose naltrexone (LDN), compounded ketamine for mental health, custom-dose pediatric liquids, compounded topical pain creams, sterile injectables, ophthalmic preparations, and hormone pellets.

The denial categories you'll actually see

Six reasons account for ~90% of all non-GLP-1 compounded denials:

1. "Plan excludes compounded drugs" — categorical exclusion buried in the pharmacy benefit summary; common in narrow formularies.

2. "Commercially available alternative exists" — even when the commercial form is mechanistically different (50 mg naltrexone vs 4.5 mg LDN) or contains an excipient the patient is allergic to.

3. "FDA non-interchangeability — not FDA-approved" — true for compounded drugs by definition, but legally permissible under DQSA.

4. "USP 795 / 797 not specified" — the prescription or pharmacy profile didn't include the standards documentation.

5. "Bulk drug substance not permissible" — the active substance is alleged not on the FDA 503A bulks list.

6. "Off-label / experimental clinical use" — most often hits LDN for fibromyalgia / MS / Crohn's, compounded ketamine for treatment-resistant depression, and BHRT for hormone replacement.

Each one has a specific counter rooted in a real federal document or clinical paper.

The federal compounding framework: DQSA §503A vs §503B

Under DQSA 2013:

§503A — Traditional compounding pharmacies. Patient-specific prescriptions, state-board oversight, exempt from FDA new-drug-approval / cGMP / labeling requirements when the pharmacy meets statutory conditions. Active substances must come from FDA-registered API suppliers and either appear in a USP/NF monograph, be a component of an FDA-approved drug, or appear on the FDA 503A bulks list. The traditional community / hospital compounding pharmacy operates here.

§503B — Outsourcing facilities. Voluntary FDA registration, follow cGMP, can produce compounded drugs without patient-specific prescriptions, and may distribute across state lines. Used by hospitals for office-administered preparations (compounded epinephrine syringes, premix vasopressors, hospital-batched preparations).

Both pathways are legal. Compounded drugs are not FDA-approved drugs but they are legally manufactured under the DQSA framework. Insurer language equating "not FDA-approved" with "experimental" misreads the statute.

USP General Chapters: the pharmacy-quality anchor

The United States Pharmacopeia (USP) maintains the controlling pharmacy-compounding standards. Three chapters apply:

• USP 795 — Pharmaceutical Compounding (Nonsterile Preparations). Master formulation records, ingredient sourcing, beyond-use dating, container-closure compatibility, training and personnel competency. Applies to creams, ointments, oral liquids, capsules, and other non-sterile preparations.
• USP 797 — Pharmaceutical Compounding (Sterile Preparations). Substantially revised in 2022. Establishes Category 1, 2, and 3 sterile compounding with specific BUDs, environmental monitoring, garbing, hood / cleanroom requirements, and sterility testing. Applies to injectables, ophthalmics, and infusions.
• USP 800 — Hazardous Drugs (Handling in Healthcare Settings). Applies to NIOSH hazardous drugs (chemotherapy, certain hormones, some immunosuppressants). Engineering controls, PPE, surface wipe sampling.

Most state pharmacy boards adopt USP 795 / 797 / 800 by reference. PCAB (Pharmacy Compounding Accreditation Board, now under ACHC) offers voluntary accreditation that documents USP compliance and is widely recognized by insurers.

When a denial cites "USP standards not specified," the appeal includes a pharmacy attestation — state license number, 503A / 503B designation, USP 795 / 797 / 800 compliance, last state-board inspection, PCAB / ACHC accreditation, API supplier list. One letter from the dispensing pharmacy answers this denial.

The FDA 503A bulks list and the "demonstrably difficult" list

Two FDA documents determine whether the active substance can be legally compounded.

FDA 503A Bulks List (interim final rule, six-category structure under DQSA §503A(b)(1)(A)(i)(III)). Most BHRT actives (estradiol USP, progesterone USP, testosterone USP, estriol USP), naltrexone HCl (the LDN active), and ketamine HCl appear in Category 1 — substances permitted in 503A compounding. The list is searchable on FDA.gov.

FDA "Demonstrably Difficult to Compound" List under DQSA §503A(b)(3)(A) and §503B(a)(6). Substances FDA has identified through Pharmacy Compounding Advisory Committee (PCAC) review as too complex to compound safely. As of 2026, this list is short. Verify on FDA.gov before citing.

When a denial alleges the active substance is not permissible, the appeal:

• Names the active and references its FDA 503A bulks list category.
• Confirms it does not appear on the "demonstrably difficult to compound" list.
• Provides the FDA URL for verification.

BHRT (bioidentical hormone replacement therapy)

Compounded BHRT — most often estradiol, estriol (Bi-Est), progesterone, and testosterone in transdermal cream, vaginal insert, troche, or pellet — is among the most-denied compounded categories.

The cleanest counter:

• NAMS 2022 Position Statement on Hormone Therapy explicitly states FDA-approved bioidenticals are preferred but acknowledges compounded BHRT for documented intolerance to commercial product, route requirement, or non-standard strength.
• Endocrine Society Clinical Practice Guideline on Menopausal Hormone Therapy (Stuenkel JCEM 2015) endorses individualized HT.
• The active substances (estradiol USP, progesterone USP, testosterone USP, estriol USP) are on the FDA 503A bulks list Category 1.

When the denial cites "commercial alternative exists":

• Submit the commercial-alternative trial log: each commercial HT product tried, dose, duration, response, AE.
• Document excipient allergy verified by allergy/immunology testing (IgE or patch). PEG, propylene glycol, lanolin, and certain polymer bases are common offenders.
• For patients requiring non-oral routes (migraine on oral, GI intolerance, breast-cancer-history considerations), document the route requirement.

When the denial cites "BHRT experimental":

• Cite NAMS 2022 and Endocrine Society 2015 by name.
• Cite the active substances' FDA bulks list categorization.
• Note that "compounded" ≠ "experimental" — every active is FDA-recognized; only the formulation is patient-specific.

Low-dose naltrexone (LDN)

LDN at 1.5–4.5 mg has clinical evidence in fibromyalgia, multiple sclerosis, Crohn's disease, and other inflammatory / autoimmune conditions. Insurers commonly deny LDN by claiming the 50 mg commercial naltrexone tablet is "available" — ignoring that subdividing a 50 mg tablet to 4.5 mg is not pharmacologically reliable.

Citations:

• Younger Pain Medicine 2013 — small RCT of LDN 4.5 mg vs placebo in fibromyalgia, pain reduction.
• Younger Pain Medicine 2009 — LDN open-label fibromyalgia pilot.
• Cree Annals of Neurology 2010 — LDN pilot RCT in MS.
• Smith American Journal of Gastroenterology 2007 — LDN in Crohn's disease.
• Subsequent series and reviews in Pain Practice, J Clin Rheumatol, and Clinical Rheumatology.

The mechanistic argument is critical: LDN at 1.5–4.5 mg appears to act through endorphin / TLR4 modulation, while naltrexone at 50 mg is a full opioid antagonist. They are mechanistically distinct uses of the same molecule. Subdividing a 50 mg tablet to 4.5 mg cannot reliably deliver the low-dose effect. Naltrexone HCl is on the FDA 503A bulks list Category 1.

A successful LDN appeal cites Younger 2013 and the additional series, documents the diagnosis (fibromyalgia, MS, Crohn's, etc.), and notes that off-label prescribing is legal and broadly accepted when supported by peer-reviewed evidence.

Compounded ketamine for treatment-resistant depression

Compounded oral / sublingual / intranasal ketamine is increasingly used for treatment-resistant depression (TRD) when Spravato (esketamine, FDA-approved 2019 for TRD) is unavailable due to access, REMS-prescriber location, cost share, or impractical in-clinic administration.

Citations:

• Wilkinson American Journal of Psychiatry 2017 — review of oral and sublingual ketamine in TRD.
• Andrade J Clin Psychiatry 2017 — review of oral ketamine pharmacology and clinical use.
• STAR*D and Maudsley for documenting prior antidepressant failures.
• Spravato (esketamine) FDA approval 2019 — the comparator commercial product.

A successful compounded-ketamine appeal:

• Documents failed standard antidepressants (SSRIs, SNRIs, augmentation) per STAR*D framework.
• Documents TRD diagnosis (typically two adequate antidepressant trials failed).
• Identifies the access barrier to Spravato (geographic, REMS, cost, in-clinic-administration impracticality).
• Cites Wilkinson 2017 and Andrade 2017 by name.
• Submits pharmacy 503A traditional or 503B compliance with Schedule III controlled-substance handling. Ketamine HCl is on the FDA 503A bulks list Category 1.

Pediatric custom-dose compounded liquids

Custom-dose pediatric liquids are among the least-controversial compounded preparations clinically — they exist because commercial strengths almost never match a young child's weight-based dose. Yet they are denied surprisingly often.

The argument:

• Document patient weight in kg.
• Document the prescribed dose in mg/kg/day.
• Confirm no commercial strength matches the calculated dose for that patient.
• Confirm the commercial form (tablet, capsule) is inappropriate (child cannot swallow, requires liquid).
• Cite the FDA Pediatric Formulation Initiative and the broader pediatric-pharmacology literature on extemporaneous compounding (Marraffa Pediatric Pharmacology and Therapeutics 2010 and earlier).
• Document the compounding pharmacy's USP 795 compliance.

Most state pharmacy laws explicitly recognize pediatric compounding as a core component of pharmacy practice, and many state boards mandate that pharmacies serving pediatric populations maintain pediatric-specific compounding capability.

Compounded topical pain creams

Compounded topical pain creams — typically combinations of gabapentin, ketamine, lidocaine, amitriptyline, baclofen, and ketoprofen in a transdermal base — are denied as "not medically necessary" or "components not FDA-approved for topical use."

The clinical argument: in elderly patients, those with renal impairment, GI intolerance to systemic gabapentin or NSAIDs, or anticoagulation, topical compounded pain cream avoids systemic AEs. The evidence is mixed (recent RCTs have produced inconsistent results) but individual ingredient evidence supports clinical use. Cite:

• Gabapentin for neuropathic pain (Backonja JAMA 1998 and subsequent — systemic evidence; topical pharmacokinetics are different).
• Topical lidocaine 5% (FDA-approved patch for postherpetic neuralgia).
• Amitriptyline topical case series and small RCTs.
• Patient-specific contraindication to systemic alternatives.

The bulk substances (gabapentin, ketamine HCl, lidocaine, amitriptyline HCl) are on the FDA 503A bulks list Category 1 when sourced through compliant suppliers.

Compounded ophthalmic preparations

Autologous serum tears for severe dry eye / GVHD ocular surface disease, fortified topical antibiotics for bacterial keratitis, and dilute anti-VEGF for off-label ophthalmic use are the most-encountered compounded ophthalmics. These are sterile preparations and require USP 797 compliance.

Citations:

• Geerling Cornea 2004 — autologous serum tears for severe dry eye.
• Tearling Cornea 2005 — autologous serum tears for ocular surface disease.
• Fortified antibiotic regimens are standard of care for bacterial keratitis when commercial preparations are inadequate.

The medical-vs-pharmacy benefit routing question

Some compounded preparations (sterile injectables, certain specialty preparations) are properly billed under the medical benefit (HCPCS / J-codes / NDC), not the pharmacy benefit. When the denial cites pharmacy-benefit exclusion, evaluate whether the preparation can be rerouted to the medical benefit. Hormone pellet implantation, for example, is often billed under medical with CPT 11981 / 11983 plus J-codes for the pellets.

For self-funded ERISA plans with categorical compounded-drug exclusions, the appeal moves to external review under ACA §2719. Independent reviewers tend to honor compounded prescriptions when commercial alternatives are documented as inappropriate.

State insurance regulations

Several states (varies by jurisdiction) prohibit blanket exclusions of compounded drugs when no commercial equivalent exists. Check the state insurance department regulations relevant to the patient's plan. State-regulated fully-insured plans are more constrained than self-funded ERISA plans on this front.

The peer-to-peer call

Compounded-drug denials carry a peer-to-peer deadline (often 14 days). Demand same-specialty review:

• For BHRT, a board-certified gynecologist or endocrinologist.
• For LDN, a rheumatologist, neurologist, or pain physician matching the indication.
• For compounded ketamine, a psychiatrist with TRD expertise.
• For pediatric custom-dose, a pediatrician.

Bring three things: the commercial-alternative failure log, the pharmacy USP / 503A attestation, and the controlling guideline citation. A peer-to-peer call with a same-specialty reviewer overturns many compounded denials without a written appeal.

Letter length and tone

A compounded-drug appeal should be 1.5 to 2 pages. Structure:

1. Header — member ID, claim #, prescription with active(s), strength(s), route, days supply, NDC / pharmacy NABP.

2. Diagnosis — ICD-10 + duration.

3. Patient-specific reason commercial product is inappropriate — excipient allergy verified, FDA shortage, custom strength unavailable, swallowing difficulty, route requirement.

4. Commercial-alternative trial / failure log — drug, dose, duration, response, AE, dates, prescriber.

5. Compounding pharmacy compliance — 503A vs 503B, state license, USP 795 / 797 / 800, PCAB / ACHC, API source.

6. Address denial reason directly — quote insurer's own coverage criteria, demonstrate each is met, cite DQSA §503A / §503B + USP 795 / 797 / 800 + FDA bulks list + clinical guideline (NAMS, Endocrine Society, Younger 2013, Wilkinson 2017).

7. Closing — request overturn within deadline, demand peer-to-peer with same-specialty reviewer.

Tone is professional, firm, evidence-driven. The reviewer responds to federal-statute citations, USP chapter numbers, and named clinical evidence — not adjectives.

When to escalate

If first-level appeal fails:

• Self-funded ERISA plans — second-level internal appeal, then external review (binding under ACA §2719). External reviewers tend to honor compounded Rx when commercial alternatives are documented as inappropriate.
• Fully-insured plans — state-mandated external review; many states have specific compounded-drug protections.
• Medicare Advantage — Independent Review Entity (IRE), then ALJ.
• Medicaid — state Fair Hearing.

Each level has its own deadline (usually 60–180 days). Compounded-drug appeals are uniquely well-suited to external review because the federal framework (DQSA, USP, FDA lists) is unambiguous and binding regulatory law.

What good looks like

A successful compounded-medication appeal:

• Quotes the insurer's own compounded-drug or pharmacy policy by name and number.
• Cites DQSA 2013 §503A or §503B, USP General Chapters 795 / 797 / 800, the FDA 503A bulks list (with category number for the active), and confirms the active is not on the FDA "demonstrably difficult to compound" list.
• Cites the controlling clinical guideline by name: NAMS 2022 (for BHRT), Endocrine Society 2015 (for menopausal HT), Younger Pain Medicine 2013 (LDN fibromyalgia), Cree Ann Neurol 2010 (LDN MS), Smith Am J Gastroenterol 2007 (LDN Crohn's), Wilkinson AJP 2017 (compounded ketamine TRD), Marraffa PPT 2010 (pediatric compounding).
• Includes commercial-alternative trial / failure log.
• Includes pharmacy compliance attestation (state license, 503A / 503B, USP 795 / 797 / 800, PCAB / ACHC, API supplier).
• Documents patient-specific factor — verified excipient allergy, FDA shortage, custom strength unavailable, route requirement.
• Demands peer-to-peer with same-specialty reviewer.
• Stays within 2 pages.

Most compounded-drug denials reverse on first appeal when the chart contains the federal-framework citations, the pharmacy compliance attestation, the commercial-alternative log, and the patient-specific factor. The work is in the documentation — once the chart is right, drafting the letter is mechanical.